Oral division
Orforglipron (Foundayo)
BCompetitive
Eli Lilly · approved
vs
Injectable division
Survodutide
LaggingC
Boehringer Ingelheim · certified
9% · 1 pt more
Efficacy
8%
Notable (+7.6) · gentler
Tolerability
Heavy (+17.3)
Oral pill
Route
Subcutaneous injection
None
Food / water rule
None
Room temperature
Storage
Refrigerated
The trade: Different divisions, so this is the trade, not a verdict. On these figures the two land at effectively the same loss (9% for the pill, 8% for the injection). Orforglipron adds convenience: a daily pill instead of a once weekly injection, no cold chain, supply that scales. With loss effectively matched, this is a choice of route: Orforglipron to avoid the needle and cold chain, Survodutide to avoid the daily pill and its routine.
Standalone, this page carries its own key: Efficacy = % body weight lost vs placebo, on the conservative estimand that counts everyone. Tolerability = AE-discontinuation over placebo (Mild 1 to 5 · Notable 5 to 10 · Heavy over 10 points). Different divisions, so efficacy is shown as raw magnitude, not a verdict. The side marked leads or gentler wins that axis.
Orforglipron verdict · Survodutide verdict · Is the pill as good as the shot? · How this is scored